ArticleFrontiers in stroke2026
Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes following
Article in Frontiers in stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: New therapeutic strategies to mitigate the devastating consequences of stroke are urgently needed, as restoration of blood flow is currently the only and limited available treatment. Methods: In our study, we employed a comprehensive combination of Results: Our results demonstrated that DX243 significantly increased ATP production following glutamate treatment and neuronal viability following OGD.Forty-eight hours after 1 h of MCAO, mice that received one subcutaneous injection of DX243 presented a reduced infarct volume and preserved motor coordination on the rotarod, while effects on open field locomotion were not statistically significant. Conclusion: These results highlight the promising neurorestorative properties of this new molecule and suggest its potential as a therapeutic agent for stroke patients. Further investigations in preclinical and clinical settings are warranted to elucidate its full therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.